Merck increases stake in Precigen

By The Science Advisory Board staff writers

October 9, 2020 -- Merck is increasing its stake in Precigen from approximately 11.6% to 14.8% of outstanding shares through a convertible note with an outstanding principal balance of $25 million. Merck remains Precigen's second-largest stakeholder.

Back in December 2018, Merck reassigned development rights for a chimeric antigen receptor (CAR) T-cell product to Precigen. Doing so meant Precigen could regain full autonomous development of the CAR T therapies in exchange for $150 million in stock and a $25 million convertible note.

The convertible note would have been converted in December of this year but is instead being exercised ahead of its designated maturity.


Copyright © 2020 scienceboard.net
 


Email Address:  

First Name:

Last Name:

Learn about ScienceBoard

Get the latest life sciences research and industry news, delivered straight to your inbox, for free.

Why subscribe?

ScienceBoard is uniquely focused on the business of research, addressing the biggest problems that the biomedical industry face. You’ll get breaking news, events coverage, and deep dives into the science that drives innovation, delivered to your inbox daily.

 
I have read and agree to the privacy policy and terms of service and wish to opt-in for ScienceBoard.net.